WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526511

CAS#: 97322-87-7

Description: Troglitazone, also known as CI991, is a potent PPAR agonist. Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for patients with diabetes mellitus type 2 in Japan Troglitazone, like the other thiazolidinediones (pioglitazone and rosiglitazone), works by activating peroxisome proliferator-activated receptors (PPARs). Troglitazone is a ligand to both PPARα and – more strongly – PPARγ.

Chemical Structure

CAS# 97322-87-7

Theoretical Analysis

MedKoo Cat#: 526511
Name: Troglitazone
CAS#: 97322-87-7
Chemical Formula: C24H27NO5S
Exact Mass: 441.16
Molecular Weight: 441.542
Elemental Analysis: C, 65.29; H, 6.16; N, 3.17; O, 18.12; S, 7.26

Price and Availability

Size Price Availability Quantity
5g USD 5950
10g USD 7950
20g USD 12650
10mg USD 265 2 Weeks
Bulk inquiry

Synonym: CI-991; CI991; CI 991; CS-045; GR 92132X; GR92132X; Prelay; Troglitazone; Rezulin, Resulin, Romozin, Noscal.

IUPAC/Chemical Name: 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione


InChi Code: InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)

SMILES Code: O=C(N1)SC(CC2=CC=C(OCC3(C)CCC4=C(C)C(O)=C(C)C(C)=C4O3)C=C2)C1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Preparing Stock Solutions

The following data is based on the product molecular weight 441.542000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ikeda T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab Pharmacokinet. 2011;26(1):60-70. Epub 2010 Dec 17. Review. PubMed PMID: 21178300. 2: Sangraula H, Paudel KR, Sharma M. Metformin and troglitazone in the treatment of female infertility associated with polycystic ovarian syndrome. JNMA J Nepal Med Assoc. 2009 Oct-Dec;48(176):335-9. Review. PubMed PMID: 21105563. 3: Yokoi T. Troglitazone. Handb Exp Pharmacol. 2010;(196):419-35. doi: 10.1007/978-3-642-00663-0_14. Review. PubMed PMID: 20020270. 4: Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet. 2006 Oct;21(5):347-56. Review. PubMed PMID: 17072088. 5: Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology. 2005 Feb;41(2):237-46. Review. PubMed PMID: 15657914. 6: Hug H, Dannecker R, Schindler R, Bagatto D, Stephan A, Wess RA, Gut J. Ontology-based knowledge management of troglitazone-induced hepatotoxicity. Drug Discov Today. 2004 Nov 15;9(22):948-54. Review. PubMed PMID: 15539136. 7: Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;(3):CD003053. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD003053. PubMed PMID: 12917943. 8: Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol. 2003 Jun;16(6):679-87. Review. PubMed PMID: 12807350. 9: Parker JC. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Adv Drug Deliv Rev. 2002 Nov 5;54(9):1173-97. Review. PubMed PMID: 12393300. 10: Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci. 2000 Oct 6;67(20):2405-16. Review. PubMed PMID: 11065164. 11: Horikoshi H, Hashimoto T, Fujiwara T. Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control. Prog Drug Res. 2000;54:191-212. Review. PubMed PMID: 10857389. 12: Sanaka M, Iwamoto Y. [Troglitazone for treatment of polycystic ovary syndrome]. Nihon Rinsho. 2000 Feb;58(2):465-70. Review. Japanese. PubMed PMID: 10707578. 13: Yamada K, Kuzuya H, Nakano T. [Cardiovascular effects of the thiazolidinedione troglitazone]. Nihon Rinsho. 2000 Feb;58(2):435-9. Review. Japanese. PubMed PMID: 10707572. 14: Yagi K, Mabuchi H. [Dyslipidemia in insulin resistance and its improvement by troglitazone]. Nihon Rinsho. 2000 Feb;58(2):426-9. Review. Japanese. PubMed PMID: 10707570. 15: Yamanouchi T. [Troglitazone]. Nihon Rinsho. 2000 Feb;58(2):389-94. Review. Japanese. PubMed PMID: 10707563. 16: Toyota T, Ueno Y. [Clinical effect and side effect of troglitazone]. Nihon Rinsho. 2000 Feb;58(2):376-82. Review. Japanese. PubMed PMID: 10707561. 17: Malik AH, Prasad P, Saboorian MH, Thiele DL, Malet PF. Hepatic injury due to troglitazone. Dig Dis Sci. 2000 Jan;45(1):210-4. Review. PubMed PMID: 10695637. 18: Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol. 2000 Jan;95(1):272-6. Review. PubMed PMID: 10638596. 19: Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet. 1999 Aug;37(2):91-104. Review. PubMed PMID: 10496299. 20: Bouvy ML, Egberts AC, Leufkens HG. [Clinical researchers and pharmaceutical industry. The examples of troglitazone and mibefradil]. Ned Tijdschr Geneeskd. 1999 Aug 21;143(34):1727-9. Review. Dutch. PubMed PMID: 10494317.